Equity Overview
Price & Market Data
Price: $4.60
Daily Change: -$0.45 / 9.78%
Range: $4.52 - $5.09
Market Cap: $508,367,872
Volume: 2,446,983
Performance Metrics
1 Week: 10.09%
1 Month: 265.0%
3 Months: 140.5%
6 Months: 41.69%
1 Year: -32.23%
YTD: 51.78%
Company Details
Employees: 155
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase 11 loss-of-function mutations for treating lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.